X4 Pharmaceuticals, Inc.XFORNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +250.44% | +215.18% | +79.08% |
| Gross Profit Growth | +0.00% | +0.00% | +458.31% | +324.62% | +94.70% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | -136.89% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | -128.34% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | -100.85% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | -100.86% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.15% | +2.60% | +10.18% | +10.72% | +531.05% |
| Weighted Average Shares Diluted Growth | +1.15% | +3.04% | +10.75% | +10.72% | +531.05% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +204.27% | +67.24% | +118.38% | +49.67% | -66.49% |
| Inventory Growth | +0.00% | +0.00% | +281.47% | +66.87% | +59.00% |
| Asset Growth | -0.55% | +15.89% | -50.07% | -8.20% | +98.34% |
| Book Value per Share Growth | -57.15% | +2058.46% | -96.18% | -6.65% | +33.28% |
| Debt Growth | +33.98% | +33.92% | -0.26% | -1.08% | -1.03% |
| R&D Expense Growth | +42.10% | -6.46% | -12.25% | -9.58% | -14.66% |
| SG&A Expenses Growth | +52.56% | -13.85% | -28.25% | -26.02% | -51.26% |